Kuluntu lwanamhlanje, ukutyeba kuye kwaba ngumngeni wezempilo kwihlabathi, kunye nokuvela kweRetatrutideinika ithemba elitsha kwizigulana ezijongene nobunzima obugqithisileyo. I-Retatrutide yiI-agonist ye-receptor kathathuukujolisaI-GLP-1R, i-GIPR, kunye ne-GCGR. Le ndlela ikhethekileyo ye-synergistic ejoliswe kwizinto ezininzi ibonisa amandla angaqhelekanga okunciphisa umzimba.
Ngoomatshini, i-Retatrutide iyasebenzaIi-receptors ze-GLP-1, ekhuthaza ukukhuselwa kwe-insulin, icinezela ukukhutshwa kweglucagon, kunye nokulibazisa ukukhutshwa kwesisu, ngaloo ndlela iphucula ukuhlutha kunye nokunciphisa ukutya. Ukuqaliswa kwayo kweGIP receptorsiphucula ngakumbi uvakalelo lwe-insulin, ilawula i-lipid metabolism, kwaye isebenza ngokubambisana ne-GLP-1 ukukhulisa iziphumo zokunciphisa ubunzima. Okubaluleke ngakumbi, ukusebenza kwayo kweii-glucagon receptors (GCGR)kwandisa inkcitho yamandla, iphucula i-hepatic gluconeogenesis inhibition, kwaye inciphisa ukuqokelelwa kwamafutha esibindi-kunye, ezi ndlela zinegalelo ekulahlekeni okukhulu kobunzima.
Kwizilingo zeklinikhi, imiphumo yokulahlekelwa kwesisindo se-Retatrutide iye yaphawuleka. Kwisifundo seklinikhi seeveki ezingama-48 kwiSigaba se-2, abathathi-nxaxheba abafumana idosi yeveki ye-12 mg ye-Retatrutide balahlekelwe ngumyinge weI-24.2% yobunzima bomzimba wabo-isiphumo esidlula kude amayeza amaninzi esintu okuncipha kwaye sisondela ekusebenzeni kotyando lwe-bariatric. Ngaphezu koko, ukulahleka kwesisindo kuyaqhubeka kuphucuka ngokuhamba kwexesha; ngeIveki 72, umyinge wokunciphisa ubunzima ufikelele malunga28%.
Ngaphandle kwesiphumo esinamandla sokunciphisa ubunzima, i-Retatrutide ikwabonisa isithembiso esikhulu ekuphuculeni iingxaki ezinxulumene nokutyeba. Inokunciphisa uxinzelelo lwegazi, iphucule iiprofayili zelipid, inciphise amanqanaba e-triglyceride, kwaye inikeze ukukhuselwa kwentliziyo-ukuzisa.izibonelelo zempilo ezibanzikubantu abaphila ngokutyeba.
Ixesha lokuposa: Jul-16-2025